Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.63 USD | -4.47% | -14.99% | -19.69% |
May. 09 | Earnings Flash (PRPH) PROPHASE LABS Posts Q1 Revenue $3.6M, vs. Street Est of $9.9M | MT |
May. 09 | Transcript : ProPhase Labs, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Business Summary
Number of employees: 113
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Diagnostic Services
56.0
%
| 108 | 88.3 % | 25 | 56.0 % | -77.06% |
Consumer Products
44.0
%
| 14 | 11.7 % | 20 | 44.0 % | +36.44% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 123 | 100.0 % | 44 | 100.0 % | -63.81% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ted Karkus
CEO | Chief Executive Officer | 64 | 09-06-14 |
Chief Operating Officer | 50 | Dec. 31 | |
Robert Morse
AUD | Comptroller/Controller/Auditor | 49 | 22-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Louis Gleckel
BRD | Director/Board Member | 68 | 09-05-31 |
Ted Karkus
CEO | Chief Executive Officer | 64 | 09-06-14 |
Warren Hirsch
BRD | Director/Board Member | 66 | 19-05-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,019,496 | 15,745,340 ( 41.41 %) | 18,940,967 ( 49.82 %) | 41.41 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
LANTERN PHARMA INC. 5.87% | 631,195 | 5.87% | 3,831,354 $ |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.69% | 69.26M | |
-18.92% | 8.22B | |
+70.43% | 4.38B | |
+12.76% | 2.81B | |
-2.28% | 2.66B | |
-15.14% | 1.75B | |
-58.41% | 1.74B | |
-16.63% | 1.47B | |
+24.33% | 1.24B | |
-50.73% | 1.03B |
- Stock Market
- Equities
- PRPH Stock
- Company ProPhase Labs, Inc.